Results 71 to 80 of about 4,829 (180)

Early Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX‐1/2 Phase 3 Studies

open access: yes
Clinical &Experimental Allergy, EarlyView.
Gordon Sussman   +15 more
wiley   +1 more source

Economic Burden of Chronic Lymphocytic Leukaemia in Australia

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1541-1551, December 2026.
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao   +4 more
wiley   +1 more source

Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
In treatment‐naïve CLL, a shortened obinutuzumab infusion was as safe as standard infusion, did not increase infusion‐related reactions, and significantly reduced chair time, improving outpatient unit efficiency. ABSTRACT Background Obinutuzumab‐based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion ...
Dominika Écsiová   +6 more
wiley   +1 more source

Age, Comorbidity Burden and Treatment Outcomes in Mature B‐Cell Lymphoproliferative Disorders: A Real‐World Study

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Introduction Treatment decisions in older patients with mature B‐cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.
Kevin Nasrinfar   +6 more
wiley   +1 more source

Scalable Arrayed T‐cell CRISPR Screening in Autologous Tumor Co‐cultures to Prioritize Combination Partners for T‐cell Engagers

open access: yesCurrent Protocols, Volume 6, Issue 11, November 2026.
Abstract T‐cell‐engaging therapies (TCE) have shown clinical promise in hematologic malignancies, but the T‐cell‐intrinsic determinants of TCE‐mediated cytotoxicity remain incompletely defined. This is in part because functional studies in patient‐derived primary samples have been technically challenging.
Keenan Ernste   +9 more
wiley   +1 more source

Salicylic Acid as a Food‐Derived Bioactive Constituent of Tiaoqi Daozhi Decoction: A Potential Functional Food Ingredient to Restoring Gut Barrier Function in Constipation‐Predominant IBS

open access: yesFood Science &Nutrition, Volume 14, Issue 11, November 2026.
Tiaoqi Daozhi Decoction (TQDZD) is a classic formulation composed of eight medicine‐food homologous botanicals. UPLC‐MS/MS profiling identified 1962 non‐redundant compounds in its aqueous extract, predominantly phenolic acids and flavonoids, of which 107 metabolites were systemically bioavailable.
Min Duan   +4 more
wiley   +1 more source

A Review on Chemical Components, Metabolism, Modern Pharmacological Actions and Food Application Prospects of Pueraria lobata, a Medicine‐Food Homologous Chinese Materia Medica

open access: yesFood Science &Nutrition, Volume 14, Issue 11, November 2026.
Pueraria lobata (PL) accumulates isoflavones, polysaccharides, and triterpenoids. Absorption, distribution, metabolism, and excretion (ADME) modulate the bioavailability of these bioactive constituents and govern their health‐promoting effects, including cardioprotection, glycemic regulation, antioxidation, anti‐inflammation, and antitumor activity ...
Jia Liu   +7 more
wiley   +1 more source

Decision‐Making on First‐Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi‐Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy

open access: yesHematological Oncology, Volume 44, Issue 6, November 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries. The introduction of targeted therapies has expanded first‐line treatment options, which differ across multiple relevant dimensions, making therapeutic decisions increasingly challenging.
Paolo Sportoletti   +10 more
wiley   +1 more source

Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – A case report

open access: yeseJHaem
The use of Bruton's tyrosine kinase inhibitors (BTKi) is rapidly increasing for patients with mantle cell lymphoma (MCL). Side effects reported so far are usually manageable.
Anna Nikkarinen, Ingrid Glimelius
doaj   +1 more source

Neurodegenerative Diseases: Epidemiology, Risk Factors, Classification, Pathophysiology, Clinical Features, Diagnosis, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neurodegenerative diseases share convergent risk architectures and pathological mechanisms, yet diverge in selective vulnerability, clinical presentation, and therapeutic responsiveness. This review integrates cross‐disease epidemiology, pathophysiology, diagnosis, and treatment, highlighting the transition from symptomatic care toward biomarker‐guided
Zimeng He   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy